Kim Jeong Yeon, Jeong Dongjun, Ahn Tae Sung, Kim Hyung Ju, Park Doo San, Park So Yong, Bae Sang Byung, Lee Sookyoung, Lee Sung Soo, Lee Moon Soo, Cho Hyun Deuk, Baek Moo Jun
Department of Pathology, Soonchunhyang University College of Medicine, Cheonan, Korea.
Ann Coloproctol. 2013 Jun;29(3):93-9. doi: 10.3393/ac.2013.29.3.93. Epub 2013 Jun 30.
Secreted protein acidic and rich in cysteine (SPARC), also known as osteonectin or basement-membrane-40 (BM-40), is a member of a family of matricellular proteins, whose functions are to modulate cell-matrix interactions, growth and angiogenesis in colorectal cancer. In this study, the expression of SPARC was evaluated and its correlations with clinicopathological parameters were investigated.
The researchers analyzed the expression patterns of SPARC by using immunohistochemistry in 332 cases of colorectal cancer of tissue microarray. The clinicopathological characteristics were defined by using the TNM criteria of the Union for International Cancer Control. Clinicopathological factors such as age, sex, histologic type of the tumor, pathologic tumor stage, TNM stage, and lymphovascular invasion were evaluated according to the SPARC expression.
The hazard ratios expressing SPARC in tumor cells, in the stroma, and in both tumor cells and the stroma were 2.10 (P = 0.036), 3.27 (P = 0.003) and 2.12 (P = 0.038), respectively. Patient survival was decreased in patient expressing SPARC in the stroma, and this result showed statistical significance (P = 0.016).
These findings suggest that SPARC expression in a tumor and in the stroma correlates with disease progression and may be used as a prognostic marker for colorectal cancer.
分泌性富含半胱氨酸的酸性蛋白(SPARC),也称为骨连接蛋白或基底膜-40(BM-40),是基质细胞蛋白家族的成员,其功能是调节结直肠癌中的细胞-基质相互作用、生长和血管生成。在本研究中,评估了SPARC的表达,并研究了其与临床病理参数的相关性。
研究人员使用免疫组织化学分析了332例结直肠癌组织芯片中SPARC的表达模式。临床病理特征根据国际癌症控制联盟的TNM标准定义。根据SPARC表达评估年龄、性别、肿瘤组织学类型、病理肿瘤分期、TNM分期和淋巴管浸润等临床病理因素。
肿瘤细胞、基质以及肿瘤细胞和基质中SPARC的风险比分别为2.10(P = 0.036)、3.27(P = 0.003)和2.12(P = 0.038)。基质中表达SPARC的患者生存率降低,这一结果具有统计学意义(P = 0.016)。
这些发现表明,肿瘤和基质中SPARC的表达与疾病进展相关,可能作为结直肠癌的预后标志物。